Overactive Bladder - Pipeline Insight, 2021

DelveInsight’s, “Overactive Bladder – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Overactive Bladder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Overactive Bladder Understanding
Overactive Bladder: Overview
Overactive bladder (OAB) is the name for a group of urinary symptoms. It is not a disease. The most common symptom is a sudden, uncontrolled need or urge to urinate. Some people will leak urine when they feel this urge. Another symptom is the need to pass urine many times during the day and night. It is a chronic medical condition which has a tremendous impact on the quality of life in both men and women. OAB affects performance of daily activities and social function such as work, traveling, physical exercise, sleep, and sexual function. A basic understanding of how the urinary system operates is needed to understand the cause of Overactive Bladder. The kidneys produce the urine and send it to the bladder. The bladder expands to holds the urine while the sphincter muscle acts as a spiget and controls the flow of urine. An understanding of the pathophysiology of OAB may facilitate effective treatment. Normal urinary function involves complex interactions between the cortex of the brain, the pons, the spinal cord (with the peripheral autonomic, somatic, and sensory afferent and efferent innervation of the lower urinary tract), and the anatomic components of the urinary tract itself. There are six antimuscarinic agents available for the treatment of OAB worldwide: oxybutynin, tolterodine, fesoterodine, trospium, darifenacin, and solifenacin. All the six antimuscarinic agents have shown similar efficacy, however their extended release versions have shown lower side effects compared to immediate release versions due to a decreased fluctuation in serum concentration.

"Overactive Bladder - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Overactive Bladder pipeline landscape is provided which includes the disease overview and Overactive Bladder treatment guidelines. The assessment part of the report embraces, in depth Overactive Bladder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Overactive Bladder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.


Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Overactive Bladder R&D. The therapies under development are focused on novel approaches to treat/improve Overactive Bladder.

Overactive Bladder Emerging Drugs Chapters
This segment of the Overactive Bladder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Overactive Bladder Emerging Drugs
• Neuronox: AbbVie/Medytox
Neuronox, an acetylcholine inhibitor is being developed by Medy-Tox for the treatment of the Overactive Bladder. The active ingredients involve Clostridium botulinum toxin type A. It is currently in the phase III stage of development. In September 2020, US drugmaker Allergan entered into a license agreement with South Korea’s Medytox under the terms of which, on closing, Allergan would pay Medytox an upfront of USD 65 million and Medytox would grant Allergan exclusive rights, worldwide outside of Korea, to develop and, if approved, commercialise certain neurotoxin product candidates currently in development, including a potential liquid-injectable product. In May 2020, AbbVie announced that it had finished its acquisition of Allergan plc following receipt of regulatory approval from all government authorities needed by the transaction agreement and approval by the Irish High Court.
• URO-902: Sumitovant Biopharma
Urovant Sciences is developing URO-902 for the treatment of the Overactive Bladder. URO-902 has the potential to be the first gene therapy for OAB patients. This innovative treatment has the capability to tackle an unmet need for patients who have failed oral pharmacologic therapies and are concerned with potential urinary retention or surgical interventions pertinent to existing third-line OAB treatments. It is currently in the phase II stage of development.
Further product details are provided in the report??..

Overactive Bladder: Therapeutic Assessment
This segment of the report provides insights about the different Overactive Bladder drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Overactive Bladder
There are approx. 15+ key companies which are developing the therapies for Overactive Bladder. The companies which have their Overactive Bladder drug candidates in the most advanced stage, i.e. Phase III include, Medytox.
• Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Overactive Bladder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Overactive Bladder: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Overactive Bladder therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Overactive Bladder drugs.

Overactive Bladder Report Insights
• Overactive Bladder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Overactive Bladder Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Overactive Bladder drugs?
• How many Overactive Bladder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Overactive Bladder?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Overactive Bladder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Overactive Bladder and their status?
• What are the key designations that have been granted to the emerging drugs?